CCND1-CDK4-mediated cell cycle progression provides a competitive advantage for human hematopoietic stem cells in vivo.

J Exp Med

Regeneration in Hematopoiesis and Animal Models in Hematopoiesis, Institute for Immunology, Institute of Virology, Center for Regenerative Therapies, Faculty of Medicine; Deep Sequencing Group SFB655, Biotechnology Center, TU Dresden, 01307 Dresden, Germany

Published: July 2015

Maintenance of stem cell properties is associated with reduced proliferation. However, in mouse hematopoietic stem cells (HSCs), loss of quiescence results in a wide range of phenotypes, ranging from functional failure to extensive self-renewal. It remains unknown whether the function of human HSCs is controlled by the kinetics of cell cycle progression. Using human HSCs and human progenitor cells (HSPCs), we report here that elevated levels of CCND1-CDK4 complexes promoted the transit from G0 to G1 and shortened the G1 cell cycle phase, resulting in protection from differentiation-inducing signals in vitro and increasing human leukocyte engraftment in vivo. Further, CCND1-CDK4 overexpression conferred a competitive advantage without impacting HSPC numbers. In contrast, accelerated cell cycle progression mediated by elevated levels of CCNE1-CDK2 led to the loss of functional HSPCs in vivo. Collectively, these data suggest that the transition kinetics through the early cell cycle phases are key regulators of human HSPC function and important for lifelong hematopoiesis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516798PMC
http://dx.doi.org/10.1084/jem.20150308DOI Listing

Publication Analysis

Top Keywords

cell cycle
20
cycle progression
12
competitive advantage
8
hematopoietic stem
8
stem cells
8
human hscs
8
elevated levels
8
human
6
cycle
5
cell
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!